Study details
Enrolling now
Dapagliflozin Trial
Northwestern University
NCT IDNCT05719714ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1/2
Target enrollment
60
Study length
about 2.7 years
Ages
18–85
Locations
1 site in IL
What this study is about
Researchers are testing if dapagliflozin, a medication for diabetes, can change the way your heart and lungs work in people with chronic kidney disease. The trial will also look at changes in substances created when our bodies break down food, drugs, or its own tissues.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Dapagliflozin 10 MG [Farxiga]
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Oral
How treatment is administered
Treatment Assignment
Randomized (Open Label)
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
dapagliflozin, antidiabetic (Dapagliflozin (SGLT2 inhibitor))
Drug routes
oral (Oral Tablet)
Body systems
Renal, Cardiology / Heart